Skip to main content

Vascularized Lymph Node Transfer (VLNT) into the Scrotum / Groin

VLNT is a physiologic microsurgical operation that transplants functional lymph nodes from a healthy donor site to a lymphedema-affected recipient. In penoscrotal lymphedema — when combined with excisional debulking — VLNT has achieved zero recurrence at median 49 mo follow-up, with scrotal-VLNT recipients showing significantly improved lymphatic transport vs excision alone.[1]

For the conservative anchor see Complex Decongestive Therapy; for the early-stage microsurgical alternative see Lymphaticovenous Anastomosis; for the broader condition see Genital Lymphedema and Giant Penoscrotal Lymphedema.

Mechanism​

MechanismDetail
NeolymphangiogenesisMaruccia 2023 — podoplanin-positive lymphatic-vessel density 7.92 ± 1.77 → 11.79 ± 3.38 vessels/mm² at 12 mo (p = 0.0008); VEGF-C upregulated in perinodal fat / infiltrating lymphatics.[2][3]
Lymph node pumpTransferred nodes absorb interstitial fluid via afferent lymphatics; HEVs route lymph into the venous circulation in close anatomical proximity to newly formed channels.[3]
Immune restorationVLNT restores T- and B-cell populations and improves dendritic-cell trafficking — explains the cellulitis reduction.[4]
Perinodal-fibrosis reductionPerinodal fibrosis is the leading cause of VLNT failure; adjunctive hyaluronidase injection reduced fibrosis by 26% and significantly enhanced lymphangiogenesis in a rodent model.[5]

Indications for Genital VLNT​

  • Advanced / end-stage penoscrotal lymphedema (ISL II late–III) with sclerosed lymphatics where LVA is not feasible.[1][6]
  • CDT-refractory disease after ≥ 6 mo of conservative therapy.[7]
  • Moderate-to-severe inguinal LN dysfunction with hypoplasia on MRL.[8]
  • Primary lymphedema — VLNT (alone or with LVA) reduced volume in 70% vs LVA-alone 25% (p = 0.035).[9]
  • Combined scrotal + LE lymphedema — simultaneous VLNT to groin / scrotum + distal LVA.[10]
  • Grade 1B AAPS evidence.[7]

Donor Site Options​

Donor sitePedicleMean LN countKey advantagesKey disadvantages
Lateral thoracicLateral thoracic a./v.3–5Preferred for scrotal VLNT (Ehrl); concealed scar; no donor-LE riskLimited pedicle length[1]
Groin (superficial inguinal)SCIA / SCIV3–6Most-studied; combinable with DIEPDonor LE risk (mitigated by reverse mapping); seroma 18–60%[21][22][23]
Omentum (gastroepiploic)Right gastroepiploic a./v.2.7 ± 2.10% donor LE; VEGF-C-rich; laparoscopic harvestRequires laparoscopy[26][28]
Submental / submandibularFacial a./v.3–5First reported free VLNT for scrotal LE; concealed scarMarginal mandibular nerve risk[29]
SupraclavicularTransverse cervical a./v.5.5 ± 2.3Abundant LNs (89.7% in Zone 2); low LE riskThoracic-duct / brachial-plexus proximity[24]
Jejunal mesentericJejunal segmental a./v.10.4 proximal0% donor LE / no nerve risk; highest LN countRequires laparotomy; bowel-ischemia risk[25][27]

For scrotal / groin VLNT specifically, lateral thoracic is the best-studied donor (Ehrl 5/9). Omentum is increasingly favored — Eaimkijkarn n = 12 laparoscopic omental VLNT: 29% mean circumference reduction, complete cellulitis resolution, 93% flap survival, no GI complications.[1][26]

Genital-Specific Techniques​

1. Free lateral-thoracic VLNT into the scrotum — Ehrl curative algorithm​

Treatment-oriented classification for giant penoscrotal lymphedema:[1]

  • Stage I (pitting) → CDT alone.
  • Stage II (non-pitting) → penoscrotal resection + primary closure.
  • Stage III (giant) → penoscrotal resection + reconstruction + free lateral-thoracic VLNT into the scrotum.

n = 9 (median follow-up 49 mo) — 0% recurrence; scrotal-VLNT recipients showed significantly improved scrotal lymphatic transport on postoperative lymphoscintigraphy; authors concluded VLNT "must be considered" for advanced disease.

2. Free submental / submandibular VLNT into the groin (Phan 2020)​

First reported free arteriovenous VLNT from the neck for scrotal lymphedema — submental + submandibular nodes on the facial pedicle anastomosed to deep inferior epigastric vessels in the groin, creating a new drainage basin for the scrotum.[29]

3. SCIP-Lymphatic Flap Transfer (SCIP-LFT) — combined soft-tissue + lymphatic reconstruction​

Pedicled SCIP-LFT combines VLNT principles with vascularized lymph-vessel transfer (VLVT) in a single flap:

  • Abdelfattah 2023 n = 26 — pedicled SCIP-lymphatic flap for partial (11) or total (15) scrotal reconstruction and penile coverage (11); 100% flap survival; cellulitis dramatically reduced (p < 0.001); GLS 6.2 → 0.05.[15]
  • Yamamoto 2022 (3R) n = 7 — radical resection (609–2,304 g) + pedicled full-thickness SCIP-LFT for scrotum ± SCIP pure-skin-perforator for penis; 0% complications, 0% recurrence at 22.7 mo; no postoperative compression required.[16]

The SCIP-LFT transfers intact superficial lymphatic vessels + nodes — now termed Lymphatic System Transfer (LYST) — potentially reducing the lymphangiogenesis required for functional recovery.[30]

4. Combined pedicled VLNT + LVA for scrotal + LE lymphedema (Abdelfattah 2020)​

Pedicled superficial inguinal LN transfer to the groin + distal LVA; at 9 mo — excess LE volume 49.6% → 9.4%, marked resolution of scrotal lymphedema, decreased dermal backflow on MRL.[10]

Outcomes​

OutcomeResultSeries
Volume reduction (UEL)42.7% (95% CI 36.7–49.7)Meta-analysis n = 432[35]
Volume reduction (LEL)21.98% (95% CI 19.8–24.4)Meta-analysis[35]
LEL volume reduction (gastroepiploic)29% mean circumferenceEaimkijkarn n = 14[26]
All-cause 24-mo volume reduction45.7% (p = 0.002)Schaverien n = 134[32]
Cellulitis reduction (UEL)−2.43 episodes/yrMeta-analysis[31]
Cellulitis reduction (LEL)−1.38 episodes/yrMeta-analysis[31]
Cellulitis reduction (all, 24 mo)97.9% (p < 0.001)Schaverien[32]
GLS improvement6.2 → 0.05 (p < 0.001)Abdelfattah n = 26[15]
Scrotal lymphatic transportSignificantly improved on lymphoscintigraphyEhrl n = 5[1]
Genital recurrence0% at 49 mo (Ehrl), 0% at 22.7 mo (Yamamoto)Combined n = 16[1][16]
QoL improvement100% (GBI +41)Abdelfattah[15]
Compression discontinuation34%Brown n = 89[33]
Flap survival93–100%Multiple[26][15][16][32][33]

Temporal Profile vs LVA​

LVA produces rapid improvement within the first 3 mo; VLNT shows slower but steady improvement over 12+ mo as neolymphangiogenesis establishes functional connections. Hahn meta-analysis shows pooled LEL improvement ~32% (LVA) vs ~40% (VLNT), with no significant difference.[2][3][34][35]

Recipient Site Selection — Orthotopic vs Heterotopic​

For genital lymphedema, the recipient is inherently orthotopic (groin / scrotum). Ehrl demonstrated that placement directly into the scrotum (rather than groin alone) gave superior scrotal lymphatic-transport improvement.[1]

For extremity lymphedema:[36][37][38]

  • Distal inset — highest pooled circumference reduction (42.2% UEL / 42.5% LEL); reduced cellulitis; improved QoL (high heterogeneity).
  • No single recipient site universally superior — tailor to disease stage, edema distribution, tissue condition.
  • Multilevel inset (groin + ankle) in primary lymphedema — higher volume reduction vs single level (p = 0.002), with lower major complications.
  • BCRL — no significant difference between proximal, distal, dual placement (p > 0.30).

Donor-Site Morbidity and Iatrogenic-LE Prevention​

The most feared complication is donor-site lymphedema. Mitigated by reverse lymphatic mapping (RLM):

  • ICG-based RLM (Pons) — ICG into foot webs identifies extremity-draining LNs; Patent Blue identifies trunk-draining LNs; identical to Tc-99 mapping in 39 patients; 0% donor LE.[39]
  • SPECT/CT RLM (Broyles) — drainage to ≥ 1 superficial inguinal region in 38.1% of 84 patients, mandating RLM; with SPECT/CT, 0% donor LE at 34.5 mo.[40]
  • Gamma-probe-guided harvest — flap mean radiotracer uptake 6.0% of extremity sentinel-node signal; extremity-draining LNs preserved.[41]
Donor siteDonor-LE riskSeromaOther
Groin0% with RLM (5–7% without)18–60% (decreasing with experience)Thigh dysesthesia 60% transient[21][22][39]
Omentum0%MinimalNo GI complications in modern series[26][33]
Submental0%RareMarginal mandibular nerve[29]
SupraclavicularVery lowRareBrachial-plexus / thoracic-duct proximity[24]
Jejunal mesenteric0%MinimalBowel-ischemia risk[25][27]
Lateral thoracic0%LowMinimal[1]

Hamdi 2021 — groin-VLNT seroma rate dropped from 60% (first 39 cases) to 18% (last 50 cases) over 12 yr — clear learning curve.[22]

VLNT Within the GL Treatment Algorithm​

Severity / findingApproach
MildCDT alone[8]
Moderate with hyperplasia, functional vesselsLVA ± CDT[8]
Moderate-severe with hypoplasia / sclerosed vesselsVLNT into groin / scrotum ± excision[1][8]
Giant / end-stageRadical excision + VLNT into scrotum (or SCIP-LFT / 3R / CHASCIP)[1][15][16]
Combined genital + LEPedicled VLNT to groin + distal LVA[10]

Key Urologic Takeaways​

  1. VLNT is the only approach that restores lymphatic drainage in advanced GL with sclerosed lymphatics — exactly where LVA fails.[1][7]
  2. Lateral thoracic VLNT into the scrotum is the best-studied donor for genital VLNT — significantly improves scrotal transport; 0% recurrence at 49 mo.[1]
  3. The SCIP-lymphatic flap (LYST) combines soft-tissue coverage with vessel + node transfer — 100% flap survival, 100% QoL improvement.[15][16]
  4. Omental and jejunal-mesenteric donor sites carry 0% donor-LE risk — preferred when groin nodes are unavailable (prior PLND).[25][26][33]
  5. VLNT benefits manifest gradually over 12–24 mo (vs LVA's rapid early effect).[2][34]
  6. Reverse lymphatic mapping is mandatory when harvesting groin nodes — ICG-based mapping equals Tc-99 accuracy without radioisotope exposure.[39][40]
  7. For patients with combined scrotal + LE lymphedema after PLND, simultaneous pedicled VLNT to groin + distal LVA addresses both compartments.[10]

See Also​

References​

1. Ehrl D, Heidekrueger PI, Giunta RE, Wachtel N. Giant penoscrotal lymphedema — what to do? J Clin Med. 2023;12(24):7586. doi:10.3390/jcm12247586

2. Maruccia M, Giudice G, Ciudad P, et al. Lymph-node transfer and neolymphangiogenesis: from theory to evidence. Plast Reconstr Surg. 2023;152(5):904e–912e. doi:10.1097/PRS.0000000000010434

3. Aschen SZ, Farias-Eisner G, Cuzzone DA, et al. Lymph-node transplantation results in spontaneous lymphatic reconnection and restoration of lymphatic flow. Plast Reconstr Surg. 2014;133(2):301–310. doi:10.1097/01.prs.0000436840.69752.7e

4. Huang JJ, Gardenier JC, Hespe GE, et al. Lymph-node transplantation decreases swelling and restores immune responses in a transgenic model of lymphedema. PLoS One. 2016;11(12):e0168259. doi:10.1371/journal.pone.0168259

5. Cheon H, Chen L, Kim SA, et al. Improved lymphangiogenesis around vascularized lymph-node flaps by periodic injection of hyaluronidase in a rodent model. Sci Rep. 2024;14(1):24430. doi:10.1038/s41598-024-74414-4

6. Guiotto M, Bramhall RJ, Campisi C, Raffoul W, di Summa PG. A systematic review of outcomes after genital lymphedema surgery. Ann Plast Surg. 2019;83(6):e85–e91. doi:10.1097/SAP.0000000000001875

7. Chang DW, Dayan J, Greene AK, et al. Surgical treatment of lymphedema — SR / meta-analysis. Plast Reconstr Surg. 2021;147(4):975–993. doi:10.1097/PRS.0000000000007783

8. Lu Q, Jiang Z, Zhao Z, et al. MR lymphography for male genital lymphedema. Medicine (Baltimore). 2016;95(21):e3755. doi:10.1097/MD.0000000000003755

9. Lindenblatt N, van den Wildenberg R, Barbon C, et al. Lymphatic reconstructive surgery in primary and secondary lymphedema. J Surg Res. 2025;316:8–17. doi:10.1016/j.jss.2025.10.023

10. Abdelfattah U, Elbanoby T, Ayad W, Elshamy M, Allam E. Treatment of secondary scrotal and lower-extremity lymphedema using combined pedicled lymph-node transfer and LVA. Microsurgery. 2020;40(8):901–905. doi:10.1002/micr.30656

15. Abdelfattah U, Elbanoby T, Hamza F, et al. Treatment of advanced male genital lymphedema with a complete functional lymphatic-system pedicled transfer. Urology. 2023;175:190–195. doi:10.1016/j.urology.2023.02.006

16. Yamamoto T, Daniel BW, Rodriguez JR, et al. Radical reduction and reconstruction for male genital elephantiasis (3R SCIP-LFT). J Plast Reconstr Aesthet Surg. 2022;75(2):870–880. doi:10.1016/j.bjps.2021.08.011

21. Liu HL, Pang SY, Lee CC. Donor-limb assessment after vascularized groin lymph-node transfer for BCRL. J Plast Reconstr Aesthet Surg. 2019;72(2):216–224. doi:10.1016/j.bjps.2018.10.013

22. Hamdi M, Ramaut L, De Baerdemaeker R, Zeltzer A. Decreasing donor-site morbidity after groin VLNT — 12-yr experience. J Plast Reconstr Aesthet Surg. 2021;74(3):540–548. doi:10.1016/j.bjps.2020.10.012

23. Liu HL, Pang SY, Lee CC, et al. Orthotopic transfer of vascularized groin lymph-node flap in BCRL — clinical, lymphoscintigraphy, mechanism. J Plast Reconstr Aesthet Surg. 2018;71(7):1033–1040. doi:10.1016/j.bjps.2018.02.015

24. Oonjitti T, Piyaman P, Apichonbancha S, Yodrabum N. Anatomic insights into the vascularized supraclavicular lymph-node flap. Sci Rep. 2025;15(1):28811. doi:10.1038/s41598-025-11090-y

25. Coriddi M, Wee C, Meyerson J, Eiferman D, Skoracki R. Vascularized jejunal mesenteric lymph-node transfer for extremity lymphedema. J Am Coll Surg. 2017;225(5):650–657. doi:10.1016/j.jamcollsurg.2017.08.001

26. Eaimkijkarn C, Kanasup N, Rattanamahattana O, et al. Laparoscopic omental lymph-node flap transfer for lower-extremity lymphedema. Int J Med Sci. 2026;23(2):720–729. doi:10.7150/ijms.125568

27. Schaverien MV, Hofstetter WL, Hall MS, Chen DN, Selber JC. Jejunal mesenteric VLNT for lymphedema — outcomes and technical modifications. Plast Reconstr Surg. 2022;149(4):700e–710e. doi:10.1097/PRS.0000000000008960

28. Howell AC, Gould DJ, Mayfield C, et al. Anatomical basis of the gastroepiploic VLNT — radiographic evaluation. Plast Reconstr Surg. 2018;142(4):1046–1052. doi:10.1097/PRS.0000000000004772

29. Phan R, Seifman MA, Dhillon R, et al. Use of submental and submandibular free vascularized lymph-node transfer for scrotal lymphedema. Microsurgery. 2020;40(7):808–813. doi:10.1002/micr.30651

30. Xu KY, Finkelstein ER, Wu S, Tadisina K, Mella-Catinchi J. LYST with pedicled SCIP. Plast Reconstr Surg. 2026. doi:10.1097/PRS.0000000000012927

31. Nicholas Jungbauer W, Solomon S, Verhey EM, et al. LVA and VLNT reduce long-term cellulitis — SR / meta-analysis. Ann Plast Surg. 2025;95(5):522–530. doi:10.1097/SAP.0000000000004508

32. Schaverien MV, Asaad M, Selber JC, et al. Outcomes of vascularized lymph-node transplantation. J Am Coll Surg. 2021;232(6):982–994. doi:10.1016/j.jamcollsurg.2021.03.002

33. Brown S, Mehrara BJ, Coriddi M, et al. A prospective study on the safety and efficacy of VLNT. Ann Surg. 2022;276(4):635–653. doi:10.1097/SLA.0000000000005591

34. Seidenstuecker K, Müller VA, Halbeisen FS, et al. Long-term comparative effectiveness of microsurgical treatments — LVA vs VLNT. J Plast Reconstr Aesthet Surg. 2026;117:26–32. doi:10.1016/j.bjps.2026.03.048

35. Hahn BA, Kleeven A, Richir MC, et al. Objectifying clinical outcomes after LVA and VLNT for extremity lymphedema — SR / meta-analysis. Microsurgery. 2025;45(3):e70050. doi:10.1002/micr.70050

36. Ramadan MR, Angelin P, Atmodiwirjo P. Recipient-site selection in VLNT — SR / meta-analysis. J Plast Reconstr Aesthet Surg. 2026;114:160–171. doi:10.1016/j.bjps.2026.01.005

37. Senger JB, Rajaii R, Slater C, Cho MJ. Proximal vs distal recipient sites for VLNT in BCRL — meta-analysis. J Clin Med. 2025;14(20):7281. doi:10.3390/jcm14207281

38. Lindenblatt N, Brugger L, Barbon C, et al. Vascularized lymphatic tissue transfer for lower-limb lymphedema — recipient-site matters. J Surg Res. 2026;323:58–70. doi:10.1016/j.jss.2026.04.006

39. Pons G, Abdelfattah U, Sarria J, Duch J, Masia J. Reverse lymph-node mapping using ICG lymphography. Plast Reconstr Surg. 2021;147(2):207e–212e. doi:10.1097/PRS.0000000000007585

40. Broyles JM, Smith JM, Wong FC, et al. SPECT/CT reverse lymphatic mapping for groin VLNT planning. Plast Reconstr Surg. 2022;150(4):869e–879e. doi:10.1097/PRS.0000000000009557

41. Dayan JH, Dayan E, Smith ML. Reverse lymphatic mapping — new technique for maximizing safety in VLNT. Plast Reconstr Surg. 2015;135(1):277–285. doi:10.1097/PRS.0000000000000822